UBS Maintains Buy on Elevance Health, Raises Price Target to $523
UBS analyst A.J. Rice maintains Elevance Health (NYSE:ELV) with a Buy and raises the price target from $460 to $523.
Share
Why It Matters
A big bank analyst believes Elevance Health is a good company to own. They think the stock could be worth more money in the future.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.